Interstitial Lung Diseases (ILDs) encompass a broad category of roughly 200 lung disorders characterized by progressive scarring of lung tissue. Understanding ILDs is crucial for healthcare professionals due to their potential to cause severe lung damage and respiratory failure.
ILDs primarily affect the interstitium - the area around the lung's air sacs (alveoli). Inflammatory or fibrotic processes lead to thickening of this interstitial space, disrupting the exchange of oxygen and carbon dioxide. This results in progressive dyspnea and impaired lung function.
ILDs are categorized based on their etiology. Idiopathic Pulmonary Fibrosis (IPF) is the most common ILD, with unknown cause. Connective tissue diseases, such as Rheumatoid Arthritis or Systemic Lupus Erythematosus, can also lead to ILDs. Occupational and environmental exposures, certain medications, and radiation therapy are other potential causes.
Diagnosis of ILDs involves a detailed medical history, pulmonary function tests, imaging studies, and sometimes, lung biopsy. Management is primarily supportive, including pulmonary rehabilitation and oxygen therapy. Antifibrotic agents like pirfenidone and nintedanib are used in IPF. In severe cases, lung transplantation may be considered.
Prognosis varies widely among ILDs, with IPF having a particularly poor prognosis. Future research is focused on elucidating the pathophysiology of ILDs and developing targeted therapies to halt or reverse the fibrotic process.
Comprehending ILDs is essential for healthcare professionals, given their impact on respiratory function and quality of life. Accurate diagnosis and management can significantly influence patient outcomes. Continuous research is vital to further our understanding and improve therapeutic options for these challenging diseases.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation